2013 - International Conference on Transplantomics and Biomarkers in Organ Transplantation


Plenary 8: Importing New Ideas

10.1 - Power of Genomics

Presenter: John, Todd, , United Kingdom
Authors: John Todd


Overview:
Our aim is to further characterise the molecular basis for the autoimmune inflammatory disease type 1 diabetes. We have used integrated combination of genetics, in large collections of type 1 diabetic families and case/control, statistics, genome informatics and data mining, and gene expression and immunological studies. Our major effort now is to correlate susceptibility genotypes with biomarkers and phenotypes e.g. we have associated flow cytometric phenotypes of T lymphocytes with disease-predisposing genotypes of the IL-2RA (CD25) gene (Dendrou, C. et al. Nat. Genet. 41, 1011-1015, 2009). This is a first step towards identifying disease precursors that could be used in future therapeutic studies to stratify patients. To achieve this we have helped build a local biobank of volunteers and type 1 diabetes patients in whom we can study the effects of disease-associated genotypes and environmental factors (Cambridge BioResource: www.cambridgebioresource.org.uk/).

These immunology studies have underpinned the next major phase of our research: undertaking clinical studies with novel clinical trial design in patients with type 1 diabetes. Our initial clinical trials will be to assess the effects and mechanisms of ultra-low-dose IL-2 on the immune system, with a focus on T regulatory cell activities. Our research efforts are part of the JDRF/Wellcome Trust Diabetes and Inflammation Laboratory (DIL), which has three other group leaders, John Todd (Director) Linda Wicker (Co-director, DIL), and Chris Wallace (Head of Statistics group)."


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi